We are live on
!
Find out more
ST
SAL Trading Portfolio holdings
AUM
$57M
1-Year Est. Return
33.89%
This Fund
S&P 500
This Quarter
Est. Return
+5.82%
1 Year Est. Return
+33.89%
3 Year Est. Return
+18.85%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$57M
AUM Growth
-$1.19M
(-2%)
Cap. Flow
-$4.21M
Cap. Flow
% of AUM
-7.38%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
17
New
5
Increased
1
Reduced
1
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rio Tinto
RIO
|
+$718K |
| 2 |
Frontline
FRO
|
+$558K |
| 3 |
ArcelorMittal
MT
|
+$451K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$6.14M |
| 2 |
British American Tobacco
BTI
|
+$924K |
| 3 |
BP
BP
|
+$848K |
| 4 |
Ferrari
RACE
|
+$613K |
| 5 |
CMBT
CMB.TECH NV
CMBT
|
+$187K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Materials | 2.3% |
| 2 | Healthcare | 1.85% |
| 3 | Energy | 0.95% |
| 4 | Consumer Discretionary | 0% |
| 5 | Consumer Staples | 0% |
No holdings matched the selected filter criteria.
Similar funds
ARC
AGFIA
SVG
TM
LOF
BCM
MAM
LAMC
SAL Trading's Q3 2024 Portfolio in Review
As of Q3 2024, SAL Trading held 17 positions worth $57M, down 2% from $58.2M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
SAL Trading withdrew a net $4.21M in Q3 2024, closing 8 positions and reducing 1 holding. Its most notable exit was AstraZeneca, an estimated $6.14M position sold in full.
By sector, the portfolio is most concentrated in Materials at 2.3% of assets, followed by Healthcare and Energy.
Against the trend, SAL Trading opened a new position in Rio Tinto worth $796K.
- SAL Trading's largest Q3 2024 buy was Rio Tinto: 11,185 shares worth $796K.
- SAL Trading fully exited AstraZeneca in Q3 2024, selling an estimated $6.14M.
- SAL Trading's ten largest holdings make up 100% of its $57M portfolio in Q3 2024.
- SAL Trading opened 5 new positions and closed 8 in Q3 2024.
- SAL Trading's portfolio value fell 2% quarter-over-quarter to $57M.
Based on SAL Trading's 13F filing for Q3 2024, filed 14 Nov 2024.